OSLO, Norway, Oct. 21, 2019 /PRNewswire/ -- Reference is made
to the stock exchange announcement on 18
October 2019 regarding the successful completion of Nordic
Nanovector ASA's (OSE: NANO) (the "Company") private placement of
new shares (the "Private Placement") The Private Placement is
divided into two tranches, as further explained in the stock
exchange announcement on 18 October
2019.
The share capital increase pertaining to the 5,511,946 new
shares, each with a nominal value of NOK
0.20, to be issued in tranche 2 (the "Tranche 2 Shares") has
been registered in the Norwegian Register of Business Enterprises
(the "NRBE") on 21 October 2019, and
the Company's share capital has been increased with NOK 1,102,389.20 through the issuance of the
Tranche 2 Shares. The Tranche 2 Shares are from this notice
tradeable on Oslo Stock Exchange, and will be delivered to the
investors on a delivery versus payment basis on 23 October 2019.
Following registration of the share capital increase related to
the Tranche 2 Shares in the NRBE, the Company has an issued share
capital of NOK 12,126,283.40, divided
into 60,631,417 shares, each with a par value of NOK 0.20.
The share capital increase pertaining to the 5,511,946 new
shares to be issued in tranche 1 is expected to be registered in
the NRBE on or about 24 October
2019.
For further information, please contact:
Malene Brondberg
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a
novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a
growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends
to retain marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets. Further
information can be found at www.nordicnanovector.com
This information is subject to the disclose requirements
pursuant to the Continuing Obligations for companies listed on the
Oslo Stock Exchange section 3.2.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa---tranche-2-share-capital-increase-registered,c2937090